Psychedelics – News and Features

Research demonstrates that rats given psilocybin exhibit increased optimism and motivation in reward-based tasks. This study provides insights into how psilocybin may address core symptoms of major depression.

A classic psychedelic was found to activate a cell type in the brain that silences other neighboring neurons, a result that provides insight into how such drugs reduce anxiety, according to a new study in mice.

Researchers found that psilocybin therapy provides long-term relief from depressive symptoms similar to escitalopram while improving overall well-being. The study highlights psilocybin’s potential as a more holistic treatment option depression.

New research has found low levels of public health participation or collaboration in psychedelic research, education, training or information dissemination.

A study found that human and dog brains synchronize during mutual gazing and petting, with increased synchronization over time. Dogs with autism-like social impairments lost this synchronization, but a single LSD treatment restored it.

A study reveals that patients face significant barriers discussing psychedelic substances with their physicians. Stigmatization, perceived lack of knowledge, and fear of damaging the doctor-patient relationship often prevent open conversations.

A study shows psilocybin and SSRIs affect brain dynamics differently in treating depression. Psilocybin induces a "flattening" of hierarchical brain structures, while SSRIs enhance hierarchical reorganization.

Study suggests that high doses of psilocybin appears to have a similar effect on depressive symptoms as the selective serotonin reuptake inhibitor escitalopram.

Dr. Sergio Pérez Rosal explains why, in his opinion, “hope is not lost” and the therapeutic potential of psychedelics for the treatment of psychiatric disorders could still be unlocked. But what happens next must be firmly rooted in science.

The US Food and Drug Administration (FDA) has rejected the use of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), according to an announcement from the therapy’s drugmaker, Lykos Therapeutics.